TAP Spectracef approval
This article was originally published in Pharmaceutical Approvals Monthly
Cefditoren pivoxil clears FDA Aug. 29 for treatment of acute exacerbation of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections. Spectracef will be launched early in the fourth quarter, just ahead of the cold and flu season. When TAP originally submitted the NDA for the antibiotic in 1999, it also sought approval for sinusitis, but the firm voluntarily withdrew the indication and is no longer pursuing it
You may also be interested in...
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Abingdon Health has announced that a study run in conjunction with the UK Rapid Test Consortium has demonstrated that its AbC-19 test could be an effective tool for testing vaccine efficacy.
NGO says the Expert Panel for Cosmetic Ingredient Safety’s conclusion on methylisothiazolinone in 2020 was among decisions “not in the interest of public health.” However, other assessments highlighted by the group suggest that the Cosmetic Ingredient Review is working as an open forum for public input and discussion.